Tuberculosis management is on track for a groundbreaking shift as the World Health Organization introduces ambitious targets for long-acting injectable medicines to spare patients from the rigorous routine of taking daily pills for months, a regimen that is often disrupted by financial constraints, long journeys to healthcare centers, or severe side effects that risk treatment failure and drug resistance. Recognizing these obstacles, the WHO published its Target Regimen Profiles for Long-Acting Injectables for Tuberculosis Prevention and Treatment on October 28, 2026, setting baseline and optimal criteria for future medications by distinguishing between preventive treatment—intended for infected individuals without active disease to reduce their risk through an ideal single-injection course during one healthcare visit—and active TB treatment, which aims to limit the duration to four months or less through three or fewer dosing encounters. These upcoming injectables are projected to match the safety and effectiveness of standard oral regimens, offering a beacon of hope particularly for India, which carries the heaviest global TB burden, even though these specifications serve as a roadmap for future drug development rather than medications ready for immediate patient use.
Single-Shot TB Prevention & Shorter Regimens: A Game-Changer in the Fight Against Tuberculosis
